β-Blockers are effective in congestive heart failure patients with atrial fibrillation
Fanbo Meng,Tsutomu Yoshikawa,Akiyasu Baba,Kazunori Moritani,Masahiro Suzuki,Toru Satoh,Hitoshi Yokozuka,Akira Murayama,Satoshi Ogawa
DOI: https://doi.org/10.1054/S1071-9164(03)00127-1
IF: 6.592
2003-01-01
Journal of Cardiac Failure
Abstract:Results Left ventricular end-diastolic dimension was decreased in AF group (n = 24) 4 weeks (early) and 16 to 48 weeks (late) after introduction of β-blockers ( P <.05, P <.001), but not in the sinus rhythm (NSR) group (n = 46). End-systolic dimension was decreased in both the AF group ( P <.01, P <.0001) and the NSR group ( P <.01, P <.0001). LVEF was increased in both the AF group ( P <.0005, P <.0001) and the NSR group ( P <.0001, P <.0001) early and late after the therapy. Increase in LVEF by the therapy tended to be higher in the AF group than in the NSR group ( P = .056). Plasma brain natriuretic peptide level did not change significantly throughout the observation period, although the level tended to be lowered in the AF group late after introduction of β-blockers ( P = .093). Conclusions Because β-blockers are effective in both NSR and AF patients with CHF, such a mode of therapy should be recommended in patients with AF. Keywords Brain natriuretic peptide norepinephrine carvedilol metoprolol Large-scale clinical trials during 1990s have established that β-blockers are useful in prolonging life expectancy in patients with congestive heart failure. 1–3 Carvedilol, a new generation β-blocker, has been shown to be safely introduced in severe congestive heart failure who has symptoms during minimal exertion. 4 Clinical trials on carvedilol in congestive heart failure demonstrated that β-blocker use reduced heart failure hospitalizations, resulting in a decrease in health care resource utilization. 5,6 However, several issues remain to be answered. One of the greatest concerns is whether or not such type of pharmacologic intervention affects favorably congestive heart failure patients with persistent atrial fibrillation. Atrial fibrillation is noted in approximately 20% of patients with congestive heart failure. 7 Presence of atrial fibrillation is associated with morbidity including exacerbation of congestive heart failure, poor exercise tolerance, and stroke. In addition, some studies suggest that presence of such arrhythmia adversely affects the prognosis in patients with heart failure. 8–11 It is, therefore, of significance to determine the efficacy of β-blockers in such a high-risk population. We attempted to determine the effects of β-blockers, including metoprolol and carvedilol, on cardiac function and neurohormones in patients with persistent atrial fibrillation in comparison with those with sinus rhythm. Methods and materials Study patients A total of 70 congestive heart failure patients with New York Heart Association class II-IV and radionuclide ejection fraction <40% who received metoprolol or carvedilol over 16 to 48 weeks were examined in the present study. Patients were prospectively enrolled in the 2 different studies, including adjunctive therapy using pimobendan in carvedilol treatment for severe heart failure and randomized comparison between metoprolol and carvedilol in mild to moderate heart failure. We retrospectively analyzed the data in relation to the baseline cardiac rhythm. The etiology of congestive heart failure was idiopathic dilated cardiomyopathy in 56 cases, ischemic cardiomyopathy in 12 cases, valvular heart disease in 1 case, and hypertensive heart disease in 1 case. Coronary angiography was performed in 49 patients, and endomyocardial biopsy was done in 28 patients. Atrial fibrillation was noted in 24 patients, and sinus rhythm was observed in the remaining 46 patients with congestive heart failure. The study protocol was approved by the institutional review board, and all patients gave informed consent to participate in the present study. Titration of β-blockers Carvedilol was administered in 49 patients and metoprolol was administered in 21 patients. The initial dose was 2.5 mg/day for carvedilol and 5.0 mg for metoprolol. The target dose was 20 mg/day for carvedilol and 80 mg/day for metoprolol. These are accepted as maximal doses of β-blocker therapy for Japanese patients with congestive heart failure. 12,13 Pimobendan was coadministered as an adjunctive therapy for 16 severely ill patients for 4 weeks after introduction of β-blockers. 14 Clinical parameters Chest roentgenogram, ultrasonic echocardiography, radionuclide ventriculography, and plasma neurohormone determination were performed at baseline and 4 weeks (early phase) and 16 to 48 weeks (late phase) after introduction of β-blockers. Late phase follow-up was performed 16 weeks after introduction of β-blockers in randomized comparison between metoprolol and carvedilol. For adjunctive therapy protocol, the follow-up was performed 24 to 48 weeks after the therapy. Plasma neurohormones included norepinephrine, epinephrine, dopamine, renin, angiotensin II, aldosterone, atrial and brain natriuretic peptide, endothelin-1, and interleukin-6. Responder was defined as an increase in the left ventricular ejection fraction of at least 5 units on radionuclide ventriculography during the observation period according to the previous report. 15 Statistical Analysis Data were expressed as mean±SD. Comparison between the 2 groups was performed with a t -test. Serial changes in various parameters over the observation period were assessed using repeated measure of analysis of variance. Difference in prevalence was assessed using the chi-square test. Statistical significance was set at P <.05. Results Baseline characteristics of the study population showed that idiopathic dilated cardiomyopathy was more common as a cause of congestive heart failure in patients with atrial fibrillation group than in those with sinus rhythm ( Table 1 ). Concomitant use of digitalis glycosides and diuretics was more common in patients with atrial fibrillation. There was no difference in age, gender, duration of illness, use of angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists, or hemodynamic variables between patients with atrial fibrillation and those with sinus rhythm. Baseline heart rate was lower in patients with atrial fibrillation than those with sinus rhythm ( Table 2 ). Left atrial dimension was larger in patients with atrial fibrillation than in those with sinus rhythm. There was no difference in other parameters including blood pressure, cardiothoracic ratio, left ventricular dimensions on echocardiography, or left ventricular ejection fraction on radionuclide ventriculography (see Table 2 ). Plasma neurohormones were also similar between the 2 groups. Heart rate was significantly decreased in patients with sinus rhythm for both early and late phases after introduction of β-blockers, but not in patients with atrial fibrillation. Systolic blood pressure tended to be lowered in both groups in the early phase with no statistical significance. There was no significant change in cardiothoracic ratio during the observation period ( Table 3 ). Left ventricular end-diastolic dimension was decreased in patients with atrial fibrillation for both early and late phases after introduction of β-blockers, but not in patients with sinus rhythm. End-systolic dimension was decreased in patients with atrial fibrillation for both early and late phases. The dimension was similarly decreased in patients with sinus rhythm ( Fig. 1 ). Left atrial dimension did not change significantly. Left ventricular ejection fraction on radionuclide ventriculography was increased in patients with atrial fibrillation and in those with sinus rhythm for early phase. Ejection fraction was also similarly increased in both groups for late phase ( Fig. 2 ). Change in ejection fraction from the baseline value was not different between patients with atrial fibrillation and those with sinus rhythm in the early phase (+7±7% versus +5±6%, NS), but tended to be higher in patients with atrial fibrillation than those with sinus rhythm in the late phase (+16±11% versus +10±13%, P = .056). Responders were slightly more common in patients with atrial fibrillation than in those with sinus rhythm (75% versus 51%, P = .056). In patients with atrial fibrillation, 19 received carvedilol and 5 received metoprolol. Left ventricular end-diastolic ( P <.001) and end-systolic dimensions ( P = .0001) and ejection fraction ( P <.0001) were improved in patients who received carvedilol over the observation period. In patients who received metoprolol, end-systolic dimension tended to be decreased ( P = .07) and ejection fraction tended to be increased ( P = .05), although statistically insignificant. End-diastolic dimension did not change significantly. Magnitude of the increase in ejection fraction did not differ between patients who received carvedilol and those who did metoprolol. There was no significant change in plasma neurohormones except for plasma endothlin-1, which was decreased in patients with normal sinus rhythm for both early and late phases after introduction of β-blockers (see Table 3 ). Plasma brain natriuretic peptide level tended to be lowered in patients with atrial fibrillation for the late phase ( P = .093), although statistically insignificant. In patients who did not receive coadministration of pimobendan, results were essentially the same except for the left ventricular end-diastolic dimension, which was significantly decreased in both patients with sinus rhythm ( P <.01, P <.005) and those with atrial fibrillation ( P <.01, P <.0005) for both early and late phases after introduction of β-blockers. Plasma endothelin-1 level tended to be decreased in the late phase, but was no longer statistically significant ( P = .059). Discussion The present study demonstrated that β-blockers including metoprolol and carvedilol were useful in alleviating left ventricular dysfunction in patients with congestive heart failure who had persistent atrial fibrillation. The magnitude of increase in left ventricular ejection fraction tended to be higher and plasma brain natriuretic peptide level tended to be lower in patients with atrial fibrillation over the observation period. Three reports has focused on the efficacy of β-blockers in patients with atrial fibrillation. The Second Cardiac Insufficiency Bisoprolol Study (CIBIS-II) compared the effects of β1-selective antagonist, bisoprolol, between patients with sinus rhythm and those with atrial fibrillation, and found that bisoprolol reduced cardiovascular mortality and heart failure hospitalization in patients with sinus rhythm, but not in those with atrial fibrillation. 16 Effects on left ventricular function or neurohormones were not described, and ischemic etiology was predominant as a cause of heart failure in this study. By contrast, carvedilol, a nonselective β1- and β2-adrenergic receptor antagonist with α1-adrenergic receptor blocking action, increased left ventricular ejection fraction in patients with atrial fibrillation from the database on US Carvedilol Heart Failure Study. 17 However, total mortality was not decreased by carvedilol compared with placebo. Fung et al 18 examined the effects of β-blockers, including metoprolol and carvedilol, in only 12 patients with congestive heart failure who had persistent atrial fibrillation. Left ventricular ejection fraction similarly improved in patients with sinus rhythm and those with atrial fibrillation, although significant improvement in symptoms and exercise capacity was noted in patients with sinus rhythm, but not in those with atrial fibrillation. In the present study, in which idiopathic cardiomyopathy was a predominant cause, left ventricular function was similarly improved in both patients with sinus rhythm and atrial fibrillation with some differential regulations in neurohormonal profile. Difference in etiology of heart failure and in study endpoints may be responsible for the inconsistent results. There are inconsistencies regarding heart rate and blood pressure response during β-blocker therapy. In the CIBIS-II study, heart rate reduction at 2 months was slightly lower in the bisoprolol group in patients with atrial fibrillation than in those with sinus rhythm. 16 The mean blood pressure decrease at 2 months was similar in patients with atrial fibrillation and in those with sinus rhythm. In the US Carvedilol Heart Failure Study, heart rate and blood pressure reduction at rest tended to be greater in patients who received carvedilol than those who received placebo in patients with atrial fibrillation, although there was no statistical significance. 17 From the findings of Fung et al, both heart rate and blood pressure were similarly decreased in patients with sinus rhythm and those with atrial fibrillation. 18 In the present study, heart rate was significantly decreased in patients with sinus rhythm, but not in those with atrial fibrillation. Differences in baseline heart rate, which were lower in patients with atrial fibrillation than in those with sinus rhythm, may be responsible for the different heart rate response between the 2 groups. Systolic blood pressure tended to be lowered in early phase in both groups, but this was not statistically significant in the present study. End-diastolic dimension was decreased in patients with atrial fibrillation, but not in those with sinus rhythm in the present study. This finding contradicts the previous report, which showed that end-diastolic dimension was decreased in patients with sinus rhythm, but not in those with atrial fibrillation. 18 When we excluded patients who received coadministration of pimobendan, end-diastolic dimension was actually decreased after administration of β-blockers in patients with sinus rhythm. In the present study, left ventricular ejection fraction was increased both in patients with sinus rhythm and those with atrial fibrillation, although the increase in left ventricular ejection fraction tended to be greater in patients with atrial fibrillation. Similarly, responders tended to be more common in patients with atrial fibrillation. Differences in the sample size appears to be responsible for the discrepancy. Data from the US Carvedilol Heart Failure Study found that carvedilol improved ejection fraction compared with placebo in patients with atrial fibrillation, but the study did not describe the difference between patients with sinus rhythm and those with atrial fibrillation. 17 In the present study, plasma brain natriuretic peptide level tended to be lower in patients with atrial fibrillation, but not in those with sinus rhythm. This finding suggests that antiremodeling effect of β-blockers is more prominent in patients with atrial fibrillation. Alternatively, use of carvedilol tended to be more common in patients with atrial fibrillation than those with sinus rhythm (79% versus 65%), although statistically insignificant. It is possible that carvedilol exerts more potent antiadrenergic effect 19 as well as antioxidant effect, 20 resulting in a more potent antiremodeling effect in patients with congestive heart failure. However, the magnitude of the increase in left ventricular ejection fraction was similar between patients who received carvedilol and those who received metoprolol in the present study. Endothelin-1 level was slightly but significantly decreased in patients with sinus rhythm. Such changes were not observed in patients with atrial fibrillation. Although it is reported that carvedilol inhibited endothelin biosynthesis in coronary endothelial system, 21 the effect of metoprolol on endothelin system remains to be determined. Significance of endothelin-1 in the clinical outcome of β-blocker therapy is still uncertain. Finally, this was a heterogeneous study of small sample size that lacks of placebo group. Plasma neurohormone levels were variable from patient to patient. Larger placebo-controlled clinical study will be required to confirm these findings. Summary β-Blockers are useful in reversing left ventricular dysfunction in both patients with sinus rhythm and those with atrial fibrillation. Increase in left ventricular ejection fraction tended to be greater and plasma brain natriuretic peptide level tended to be lowered in patients with atrial fibrillation. These findings demonstrate that β-blockers have beneficial effects on left ventricular remodeling in patients with atrial fibrillation that are at least as good as the improvements seen in sinus rhythm. References 1. M Packer M.R Bristow J.N Cohn W.S Colucci M.B Fowler E.M Gilbert The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355 2. CIBIS II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial Lancet 353 1999 9 13 3. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Study Group Effect of metoprolol CR/XL in chronic heart failure Lancet 353 1999 2001 2007 4. M Packer A.J Coats M.B Fowler H.A Katus H Krum P Mohacsi Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658 5. M.B Fowler M Vera-Llonch G Oster M.R Bristow J.N Cohn W.S Colucci Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs J Am Coll Cardiol 37 2001 1692 1699 6. M Packer M.B Fowler E.B Roecker A.J.S Coats H.A Katus H Krum Effect of carvedilol on the morbidity of patients with severe chronic heart failure Circulation 106 2002 2194 2199 7. P.E Carson G.R Johnson W.B Dunkman R.D Fletcher L Farrell J.N Cohn The influence of atrial fibrillation on prognosis in mild to moderate heart failure: V-HeFT Studies Circulation 87 1993 VI-102 VI-110 8. H.R Middlekauff W.G Stevenson L.W Stevenson Prognostic significance of atrial fibrillation in advanced heart failure Circulation 84 1991 40 48 9. P.A Wolf J.B Mitchell C.S Baker W.B Kannel R.B D'Agostino Impact of atrial fibrillation on mortality, stroke, and medical costs Arch Intern Med 158 1998 229 234 10. E.J Benjamin P.A Wolf R.B D'Agostino H Silbershatz W.B Kannel D Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952 11. D.L Dries D.V Exner B.J Gersh M.J Domanski M.A Waclawiw L.W Stevenson Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction J Am Coll Cardiol 32 1998 695 703 12. Y Yokota H Nomura H Kawai Y Tsumura Y Takeuchi H Kurozumi Effects of long-term β-blockade (metoprolol) therapy in patients with dilated cardiomyopathy Jpn Circ J 55 1991 343 355 13. K Hirooka Y Yasumura Y Ishida A Hanatani S Nakatani K Komamura Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy Jpn Circ J 65 2001 931 936 14. T Yoshikawa A Baba M Suzuki H Yokozuka Y Okada K Nagami Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure Am J Cardiol 85 2000 1495 1497 15. B.D Lowes E.M Gilbert W.T Abraham W.A Minobe P Larrabee D Ferguson Myocardial gene expression in dilated cardiomyopathy treated with beta-adrenergic blocking agents N Engl J Med 346 2002 1357 1365 16. P Lechat J Hulot S Escolano A Mallet A Leizorovicz M Werhlen-Grandjean Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial Circulation 103 2001 1428 1433 17. J.A Joglar A.P Acusta N.H Shusterman K Ramaswamy R.C Kowal S.J Barbera Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trial Program Am Heart J 142 2001 498 501 18. J.W.H Fung S.K.W Chan L.Y.C Yeung J.E Sanderson Is beta-blockade useful in heart failure patients with atrial fibrillation? Eur J Heart Failure 4 2002 489 494 19. E.M Gilbert W.T Abraham S Olsen B Hattler M White P Mealy Comparative hemodynamic left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart Circulation 94 1996 2817 2825 20. K Nakamura K Kusano Y Nakamura M Kakishita K Ohta S Nagase Carvedilol decreases elevated oxidative stress in human failing myocardium Circulation 105 2002 2867 2871 21. E.H Ohlstein A.J Atleth B Storer A.M Romanic Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells J Mol Cell Cardiol 30 1998 167 173